



HAL
open science

COLD-PCR HRM: A HIGHLY SENSITIVE DETECTION METHOD FOR IDH1 MUTATION

Blandine Boisselier, Yannick Marie, Marianne Labussière, Pietro Ciccarino,
Virginie Desestret, Xiaowei Wang, Laurent Capelle, Jean-Yves Delattre, Marc
Sanson

► **To cite this version:**

Blandine Boisselier, Yannick Marie, Marianne Labussière, Pietro Ciccarino, Virginie Desestret, et al.. COLD-PCR HRM: A HIGHLY SENSITIVE DETECTION METHOD FOR IDH1 MUTATION. Human Mutation, 2010, 31 (12), pp.1360. 10.1002/humu.21365 . hal-00591287

HAL Id: hal-00591287

<https://hal.science/hal-00591287>

Submitted on 9 May 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



COLD-PCR HRM: A HIGHLY SENSITIVE DETECTION METHOD FOR IDH1 MUTATION

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0259.R1
Wiley - Manuscript type:	Methods
Date Submitted by the Author:	09-Aug-2010
Complete List of Authors:	<p>Boisselier, Blandine; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière UMR-S975; INSERM U975; CNRS, UMR 7225</p> <p>Marie, Yannick; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière UMR-S975; INSERM U975; CNRS, UMR 7225</p> <p>Labussière, Marianne; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière UMR-S975; INSERM U975; CNRS, UMR 7225</p> <p>Ciccarino, Pietro; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière UMR-S975; INSERM U975; CNRS, UMR 7225</p> <p>Desestret, Virginie; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière UMR-S975; INSERM U975; CNRS, UMR 7225; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R. Escourolle</p> <p>Wang, XiaoWei; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière UMR-S975; INSERM U975; CNRS, UMR 7225</p> <p>Capelle, Laurent; hôpital de la Salpêtrière, Dept of Neurosurgery</p> <p>Delattre, Jean-Yves; hôpital de la Salpêtrière, Service de neurologie Mazarin</p> <p>Sanson, Marc; Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de la Moëlle épinière UMR-S975; INSERM U975; CNRS, UMR 7225; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2</p>
Key Words:	IDH1 mutations, COLD PCR, High Resolution Melting, glioma, diagnostic marker

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For Peer Review

1
2
3 **COLD PCR HRM: A HIGHLY SENSITIVE DETECTION METHOD FOR *IDH1***
4
5
6 **MUTATION**
7
8
9
10
11
12
13
14

15 Blandine Boisselier^{1,2,3}, Yannick Marie^{1,2,3}, Marianne Labussière^{1,2,3}, Pietro Ciccarino^{1,2,3},
16
17 Virginie Desestret^{1,2,3,5}, XiaoWei Wang^{1,2,3}, Laurent Capelle⁴, Jean-Yves Delattre^{1,2,3,6}, Marc
18
19 Sanson^{1,2,3,6}
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Affiliations:**
34
35

- 36 1. Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de
37
38 la Moëlle épinière (CRICM) UMR-S975, Paris 75013, France
39
40
41 2. INSERM U 975, Paris 75013, France
42
43
44 3. CNRS, UMR 7225, Paris 75013, France
45
46
47
48 4. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Neurosurgery, Paris 75013,
49
50 France
51
52
53 5. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R.
54
55 Escourolle, Paris 75013, France.
56
57
58 6. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris 75013, France
59
60

1
2
3
4
5
6 **Correspondance to** Dr Marc Sanson, Service de Neurologie Mazarin, Groupe Hospitalier
7
8 Pitié-Salpêtrière, 75651, Paris cedex 13, France.

9
10
11 Tel: +33 1 42 16 05 73 Fax: +33 1 42 16 03 75; marc.sanson@psl.ap-hop-paris.fr
12
13
14
15
16
17

18 **Abbreviations:**

19
20
21 AII: astrocytoma; COLD PCR: co-amplification al lower denaturation temperature PCR;
22
23 HRM: high resolution melting; IDH1: isocitrate dehydrogenase 1; OAI: oligoastrocytoma;
24
25
26 OII: oligodendroglioma.
27
28
29
30
31
32

33 **Disclosures**

34
35
36 The authors report no disclosures.
37
38
39
40
41

42 **Competing interests**

43
44
45 No potential conflicts of interest were disclosed.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Isocitrate dehydrogenase 1 R132H (*IDH1*^{R132H}) mutation is a frequent alteration and a major prognostic marker in gliomas. However, direct sequencing of highly contaminated tumor samples may fail to detect this mutation. Our objective was to evaluate the sensitivity of a newly described amplification method, coamplification at lower temperature-PCR (COLD PCR), combined with high resolution melting (HRM) for the detection of *IDH1*^{R132H} mutation. To this end, we used serial dilutions of mutant DNA with wild type DNA. PCR-HRM assay detects *IDH1*^{R132H} mutation at an abundance of 25%, similar to the detection limit of direct Sanger sequencing. Introducing a run of COLD PCR allows the detection of 2% mutant DNA. Using two consecutive runs of COLD PCR, we detected 0.25% mutant DNA in a background of wild type DNA, that mimicks a tumor sample highly contaminated by normal DNA. We then analyzed ten biopsies of tumor edges, considered free of tumor cells by histological analysis, and showed that immunohistochemistry of *IDH1*^{R132H} was positive in 3 cases (30%), whereas double COLD PCR HRM was positive in the ten cases studied (100%). In summary, COLD PCR HRM analysis is 100-fold more sensitive than Sanger sequencing, rendering this rapid and powerful strategy particularly useful for samples highly contaminated with normal tissue.

Keywords: *IDH1*^{R132H} mutation, COLD PCR, High Resolution Melting, glioma

Introduction

In recent years, recurrent mutations of the gene encoding isocitrate dehydrogenase 1 (*IDH1*; MIM# 147700) have been described at a high frequency in gliomas [Balss, et al., 2008; Bleeker, et al., 2009; Hartmann, et al., 2009; Ichimura, et al., 2009; Parsons, et al., 2008; Sanson, et al., 2009; Yan, et al., 2009]. Mutations in the *IDH1* gene always affect the codon 132, which in more than 90% of cases result in a substitution of arginine by a histidine residue, *IDH1*^{R132H} [Ichimura, et al., 2009; Sanson, et al., 2009; Yan, et al., 2009]. Since it is almost exclusively found in gliomas, *IDH1* mutation has a strong diagnostic value [Yan, et al., 2009]. *IDH1* mutation is also a powerful independent prognostic factor in gliomas [Dubink, et al., 2009; Nobusawa, et al., 2009; Sanson, et al., 2009]: patients with an *IDH1*^{R132H} mutated tumor having a longer survival when compared with those non mutated for the same grade. Given its diagnostic and prognostic potential, the determination of *IDH1* status in glioma samples is gaining increasing attention in clinical practice.

Conventional PCR followed by Sanger sequencing is currently the gold standard in identifying *IDH1* mutations in tumor DNA. Typically, clinical tumor samples are contaminated by normal tissue, thereby diluting the total amount of genetic that is present, and techniques are often required to identify low level alterations within an excess of wild-type DNA. This is particularly true for gliomas which are highly infiltrating tumors [Furnari, et al., 2007]. Conventional PCR enables mutation detection from a very small amount of sample but does not selectively amplify the mutant sequences. Therefore, unless the mutation exceeds a 20-25% abundance relative to wild-type alleles, conventional PCR followed by downstream methods such as Sanger sequencing will fail to detect mutations in clinical samples [Li, et al., 2009; Zuo, et al., 2009]. Enrichment methods are thus necessary to increase the mutant DNA /wild type DNA *ratio*. Tumor-cell enrichment methods, such as cell

1
2
3 sorting or microdissection, are expensive and time-consuming [Zuo, et al., 2009], and
4
5 therefore inadequate for clinical routine use.
6
7

8
9 Recently, co-amplification at lower denaturation temperature PCR (COLD PCR) has
10
11 been described as a powerful method to identify low-level mutations in the *TP53* gene [Li, et
12
13 al., 2008; Milbury, et al., 2009]. This approach uses a critical temperature (T_c) during the
14
15 PCR process in order to enrich mutations at any position of the amplified sequence. Indeed, a
16
17 single nucleotide mismatch anywhere along a double-stranded DNA sequence generates a
18
19 small change in the melting temperature for that sequence, with mutated sequences melting at
20
21 a lower temperature than wild-type sequences [Li, et al., 2008]. During COLD PCR, the
22
23 denaturation temperature is set to T_c , thereby mutation-containing sequences are
24
25 preferentially denatured and available for primers binding and subsequent amplification. High
26
27 Resolution DNA Melting (HRM) analysis is a relatively new and rapid method for detecting
28
29 DNA sequence variants following an initial amplification [Erali, et al., 2008; Vossen, et al.,
30
31 2009; Wittwer, 2009]. Gene scanning by HRM depends on the recognition of changes in the
32
33 shape of the amplicon melting curve that result from heterozygous sequence alterations [Erali,
34
35 et al., 2008]. At the end of PCR amplification, samples are heated to 95°C to ensure a
36
37 complete denaturation. Next, the temperature is reduced to allow cross-hybridization between
38
39 wild-type and mutant sequences, leading to the formation of mismatched heteroduplexes,
40
41 which melt at a lower temperature than wild-type and mutant homoduplex [Vossen, et al.,
42
43 2009]. In this study, we evaluated the sensitivity of different COLD PCR HRM assays for the
44
45 detection of *IDH1*^{R132H} mutation in glioma samples.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Material and methods

DNA and tumors samples

Tumor samples were selected from the Pitié-Salpêtrière brain tumor database. Tumor DNA was extracted from frozen tissues using the QIAmp DNA according to the manufacturer instructions (Qiagen). Samples used in this work have previously been tested for the presence of *IDH1* mutation (reference sequence NM_005896.2) by direct sequencing, as already described [Parsons, et al., 2008; Yan, et al., 2009].

Determination of T_c

We applied the fast COLD PCR assays for detecting *IDH1* mutation based on the methodology described in the literature [Li, et al., 2008], with several modifications. We first determined the new denaturation temperature T_c for the reaction. We used the same primers as for conventional PCR assay, which produced an amplicon of 172 bp. To identify the optimal critical denaturation temperature T_c , a series of COLD PCR reactions at graded temperatures below T_m were performed. We then set the T_c at 81°C, the lowest temperature that reproducibly yielded a substantial PCR. In fast COLD PCR, the reaction protocol began with 20 cycles of conventional amplification for an initial build-up of all amplicons, followed by 30 COLD PCR cycles to selectively enrich for T_m -reduced mutant sequences (Figure 1). COLD PCR assays were performed on a LightCycler480 (Roche Diagnostics Corporation) to ensure a precise control of temperature during the experiments.

Comparison of sensitivities of the different assays to detect *IDH1* mutation

To determine if COLD PCR could enhance the sensitivity of *IDH1*^{R132H} mutation detection, we compared the sensitivity of three experimental protocols. Exon 4 of the *IDH1*

1
2
3 gene was first amplified either by conventional PCR or by fast COLD PCR. A second round
4
5 of amplification was then performed either by PCR HRM, or by fast COLD PCR HRM
6
7 (Figure 2).
8
9

10
11
12
13
14
15 To compare the sensitivity of the different assays, we performed a serial dilution study
16
17 using a gDNA sample from a grade II oligoastrocytoma patient containing an *IDH1*^{R132H}
18
19 mutation as the source of the mutant allele. This mutation-containing gDNA sample was
20
21 serially diluted into wild-type gDNA (ie blood constitutive gDNA from the same patient) to
22
23 the following percentages: 25%, 10%, 8%, 5%, 4%, 2%, 1%, 0.5%, 0.25%, 0.1%, and 0.05%.
24
25
26 In addition, wild-type gDNAs (n=7) were included in each experiment. The same experiment
27
28 was reproduced with several other mutated DNA samples: another CGT→CAT mutation
29
30 (Arg132His), and also with other, less frequent mutations, such as CGT→CTT (Arg132Leu)
31
32 and CGT→AGT (Arg132Ser).
33
34
35
36
37
38

39 **First round of amplification**

40
41
42 Each PCR amplification reaction contained 50ng gDNA. PCR cycling conditions for
43
44 the first round consisted of an initial denaturation step at 94°C for 5 min; 40 cycles of 94°C
45
46 for 30s; 60°C for 1 min; and 72°C for 1 min30; and final extension at 72°C for 7 min. The
47
48 reactions were carried out using a Mastercycler (Eppendorf). Conventional PCR reactions
49
50 contained final reagent concentrations as follows: 1x PCR Master Mix (Abgene), 0.25 μM
51
52 forward and reverse primers (Invitrogen; Table I) and DNA template. COLD PCR cycling
53
54 conditions on LightCycler480 (Roche Diagnostics Corporation) are summarized as follows:
55
56 96°C, 10 min; 20 cycles of 95°C, 15s; 60°C, 30s, then 30 cycles of 81°C, 15s; 60°C, 30s.
57
58
59
60

1
2
3 COLD PCR assays contained final reagent concentrations as follows: LightCycler480 HRM
4
5 Master (Roche Diagnostics Corporation), 0.25 μ M forward and reverse primers (Invitrogen),
6
7
8 3 mM MgCl₂ and DNA template.
9

10 11 12 13 14 **Second round of amplification** 15

16
17 PCR amplification was performed with the LightCycler480 (Roche Diagnostics
18 Corporation). Each reaction contained diluted PCR amplicons (1/1000), 0.25 μ M forward and
19
20 reverse primers (Invitrogen, Table I), 3 mM MgCl₂ and LightCycler480 HRM Master (Roche
21
22 Diagnostics Corporation). PCR HRM cycling conditions were as follows: 96°C, 10min; 40
23
24 cycles of 95°C, 30s; 60°C, 30s. COLD PCR HRM cycling conditions are summarized as
25
26 follows: 96°C , 10min; 20 cycles of 95°C, 15s; 60°C, 30s, then 30 cycles of 81°C (T_c), 15s;
27
28 60°C, 30s. After amplification, a post amplification melting curve program was initiated by
29
30 heating to 95°C for 1 min, cooling to 40°C for 1 min, and increasing the temperature to 95°C
31
32 while continuously measuring fluorescence at 25 acquisitions per degree. Each PCR run
33
34 contained a negative (no template) control and each amplification was duplicated.
35
36
37
38
39
40
41

42 **High Resolution Melting (HRM) analysis and direct sequencing** 43 44

45 At the end of the second round of amplification, fluorescent melting curves were
46
47 analyzed using LC480 Gene Scanning software V1.2.9 (Roche Diagnostics Corporation). All
48
49 curves were analyzed following normalization, temperature shifting, automated grouping, and
50
51 the inspection of difference plots. The grouping software uses a curve shape-matching
52
53 algorithm in order to identify wild type from mutant samples. The 0.2 value was chosen for
54
55 the grouping sensitivity in all experiments.
56
57
58
59
60

1
2
3 Products of each assay were then submitted to the sequencing reaction using the
4 BigDye Terminator v3.1 Sequencing Kit (Applied Biosystems) as previously described
5 [Sanson, et al., 2009]. After a purification step using BigDye Xterminator Purification Kit
6 (Applied Biosystems), both forward and reverse sequences were determined on an ABI prism
7 3730 DNA analyzer (Perkin Elmer).
8
9

16 **Tumor sample selection and immunohistochemical detection of *IDH1*^{R132H}**

18
19 Tumors were retrieved from the neuropathology department database according to the
20 following criteria: histological diagnosis of WHO grade II gliomas; presence of *IDH1*^{R132H}
21 mutation confirmed by Sanger sequencing; availability of frozen and paraffin embedded
22 samples of tumor core and tumor edge, with edge biopsies considered as free of infiltrated
23 tumor cells by standard HE staining.
24
25
26
27
28
29

30
31 Immunohistochemical staining for *IDH1*^{R132H} was performed on 4 µm paraffin
32 sections of formalin-fixed tumor samples using mouse monoclonal anti-R132H-IDH1
33 antibody culture supernatant (a generous gift from Pr A. von Deimling), as previously
34 published [Capper, et al., 2010; Capper, et al., 2009]. Local immunohistochemistry protocol
35 was validated on gliomas samples which were previously analysed by Sanger sequencing for
36 *IDH1*^{R132H} mutation (positive and negative controls). Labelling was defined as positive (at
37 least one cluster of positive tumor cells) or negative (no positive tumor cells detected).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Determination of the sensitivity with dilution studies

To identify the most sensitive method for detecting *IDH1* mutation, we evaluated two techniques after a first stage of conventional PCR: the PCR HRM assay and the COLD PCR HRM assay. In a third assay, we replaced the first conventional PCR by a run of COLD PCR (Figure 2). The sensitivity of the three assays was compared using a dilution series obtained by mixing DNA from heterozygous positive control carrying the *IDH1* R132H mutation with wild-type DNA from peripheral blood.

Conventional PCR HRM assay detects mutant DNA at a concentration of 25% in a background of wild-type DNA (Figure 3A). In contrast, the COLD PCR HRM assay detects *IDH1*^{R132H} mutation at a much lower concentration: mutant DNA diluted into wild-type DNA to a 2% abundance was still clearly differentiated from normal sequences (Figure 3B). Therefore, the COLD PCR HRM assay produced an approximately 10-fold improvement in the *IDH1* mutation detection, as compared to the conventional PCR HRM analysis. Replacing the first conventional PCR amplification by a run of COLD PCR further enhanced selective enrichment of the mutant DNA and improved the detection of *IDH1*^{R132H} mutation. In these conditions, we were able to detect mutant DNA at a concentration as low as 0.25% in mixture with wild-type DNA (Figure 3C). Thus, the double COLD PCR HRM assay for the detection of *IDH1*^{R132H} mutation was 100-fold more sensitive than the PCR HRM assay.

To both confirm the selective mutation enrichment and to exclude false positive results, amplicons produced at the end of the three assays were submitted to direct sequencing using the Sanger method. The sequencing chromatograms are presented in Figure 3D. In all three cases, direct sequencing confirmed the presence of the *IDH1*^{R132H} mutation. After

1
2
3 double COLD PCR HRM with 0.25% of mutant DNA/wild DNA, *IDH1*^{R132H} mutation was
4
5 evident as clearly as for 25% with conventional PCR HRM and 2% with COLD PCR HRM.
6
7

8
9 The same results were obtained with another glioma with CGT→CAT mutation (Arg132His),
10
11 and also with less frequent *IDH1*¹³² mutations CGT→CTT (Arg132Leu) and CGT→AGT
12
13 (Arg132Ser) (supplementary figure).
14
15

16
17
18
19
20 **Comparison of PCR HRM, COLD PCR HRM and double COLD PCR HRM and**
21
22 ***IDH1*^{R132H} immunohistochemistry in biopsies of tumor edges.**
23
24

25
26 To definitely validate the clinical interest of our technique, we selected 10 pairs of
27
28 tumor core and tumor edge (one astrocytoma, 5 oligodendrogliomas, and 4
29
30 oligoastrocytomas), and performed *IDH1*^{R132H} mutation detection by both
31
32 immunohistochemistry and molecular techniques (Table II). *IDH1*^{R132H}
33
34 immunohistochemistry was positive in 3 cases (30%, 2 grade II oligodendrogliomas, and one
35
36 grade II oligoastrocytoma) showing a cytoplasmic granular staining as previously described
37
38 [Capper, et al., 2010]. Figure 4A presents the results of immunohistochemistry staining for
39
40 patient 8 in the tumor core and in the biopsy edge (lower panel). PCR HRM was positive in 8
41
42 cases out of 10 (80.0%; Figure 4B upper panel). In contrast, both COLD PCR HRM (data not
43
44 shown) and double COLD PCR HRM were positive in all cases (100%; Figure 4B, lower
45
46 panel, and table II).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Gliomas are characterized by a highly invasive phenotype, with tumor cells invading the brain at a distance far from the bulk of tumor [Furnari, et al., 2007]. Therefore biopsy samples are often contaminated by normal brain tissue, and mutated DNA is diluted in a the background of wild-type DNA from surrounding brain tissue, vasculature, and infiltrating lymphocytes [Dobrowolski, et al., 2009]. Because *IDH1*^{R132H} mutation is almost restricted to gliomas [Yan, et al., 2009], it has a major diagnostic potential. Therefore a fast and reliable scanning technique to detect this mutation in clinical samples with very few tumor cells (and appearing therefore normal at neuropathological analysis) is particularly important. In addition *IDH1*^{R132H} mutation is a major prognostic factor [Sanson, et al., 2009; van den Bent, et al., 2010]. Simple HRM has been very recently reported as a fast and sensitive strategy, detecting IDH1 and IDH2 mutations in a 90% normal DNA background [Horbinski, et al., 2010]. In this study, we used fast COLD PCR to selectively amplify *IDH1*^{R132H} mutated DNA and we showed that double COLD PCR HRM assay is a highly reliable method to detect *IDH1* mutation in samples with very few tumor cells (up to 0.25% mutated/non mutated DNA). In addition, this assay is fast (less than three hours) and therefore particularly suitable for routine diagnosis purposes in neuropathology.

Despite *IDH1*^{R132H} accounts for more than 90% of *IDH1* mutations reported in gliomas, other mutations have been described: CGT→AGT, CGT→CTT CGT→GGT, CGT→TGT [Balss, et al., 2008; Gravendeel, et al., 2010; Sanson, et al., 2009; Yan, et al., 2009]. Fortunately, all these mutations, except the CGT→GGT change, result in a lower T_m, rendering them theoretically detectable by our simple double COLD PCR assay. Indeed we were able to detect some of these less frequent mutations (supplementary figure). For the detection of CGT→GGT, a full COLD PCR assay –allowing the enrichment of all possible

1
2
3 mutations- could be performed, though the selective amplification *ratio* will probably be
4
5 lower than in fast COLD PCR, because amplification, and thus enrichment in mutant
6
7 sequences, begins earlier during cycling in fast COLD PCR than in full COLD PCR [Li, et al.,
8
9 2008; Milbury, et al., 2009].
10
11

12
13 We showed that double COLD PCR HRM (followed by sequencing in case of aberrant
14
15 HRM profiles) is a powerful method to evidence the presence of tumor cells with IDH1
16
17 mutation in apparently “blank” biopsies of grade II gliomas, and is much more sensitive than
18
19 immunohistochemistry for *IDH1*^{R132H}. Such procedure may be particularly useful in lesions
20
21 radiologically highly suggestive of glioma, whose biopsy appears non contributive because of
22
23 the very low proportion of tumor cells. In such cases, finding an *IDH1* mutation will confirm
24
25 the diagnosis of glioma, avoiding a further invasive procedure to establish diagnosis.
26
27 Moreover, such approach could also be suitable for *IDH1*^{R132H} mutation detection in the
28
29 cerebral spinal fluid thus confirming glioma diagnosis without the need for surgery.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

Work supported by the Association pour la Recherche sur les Tumeurs Cérébrales (ARTC) and the Association pour la Recherche contre le Cancer (ARC). ML is supported by a grant from the Association pour la Recherche contre le Cancer (ARC). We are indebted to Pr A von Deimling for providing the mouse monoclonal anti-R132H-IDH1 antibody and to Alice Brunner for editing the manuscript.

For Peer Review

References

- 1
2
3
4
5
6
7
8 Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 2008. Analysis of the IDH1
9 codon 132 mutation in brain tumors. *Acta Neuropathol* 116:597-602.
- 10 Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles
11 M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A.
12 2009. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas
13 but not in other solid tumors. *Hum Mutat* 30:7-11.
- 14 Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A,
15 Zentgraf H, Hartmann C, von Deimling A. 2010. Characterization of R132H Mutation-specific
16 IDH1 Antibody Binding in Brain Tumors. *Brain Pathol* 20:245-54.
- 17 Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. 2009. Monoclonal antibody specific for
18 IDH1 R132H mutation. *Acta Neuropathol* 118:599-601.
- 19 Dobrowolski SF, Hendrickx AT, van den Bosch BJ, Smeets HJ, Gray J, Miller T, Sears M. 2009.
20 Identifying sequence variants in the human mitochondrial genome using high-resolution melt
21 (HRM) profiling. *Hum Mutat* 30:891-8.
- 22
23
24 Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg
25 CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den
26 Bent MJ. 2009. IDH1 mutations in low-grade astrocytomas predict survival but not response
27 to temozolomide. *Neurology* 73:1792-5.
- 28 Erali M, Voelkerding KV, Wittwer CT. 2008. High resolution melting applications for clinical laboratory
29 medicine. *Exp Mol Pathol* 85:50-8.
- 30 Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN,
31 Brennan C, Chin L, DePinho RA, Cavenee WK. 2007. Malignant astrocytic glioma: genetics,
32 biology, and paths to treatment. *Genes Dev* 21:2683-710.
- 33 Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE,
34 Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Smitt PA, French PJ. 2010. Segregation
35 of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. *Hum Mutat*
36 31:E1186-99.
- 37
38
39 Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C,
40 Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G,
41 von Deimling A. 2009. Type and frequency of IDH1 and IDH2 mutations are related to
42 astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta*
43 *Neuropathol* 118:469-74.
- 44 Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN. 2010. Detection of IDH1 and IDH2
45 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. *J Mol*
46 *Diagn* 12:487-92.
- 47
48 Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP. 2009. IDH1
49 mutations are present in the majority of common adult gliomas but rare in primary
50 glioblastomas. *Neuro Oncol* 11:341-7.
- 51 Li J, Milbury CA, Li C, Makrigiorgos GM. 2009. Two-round coamplification at lower denaturation
52 temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-
53 level mutations in lung adenocarcinoma. *Hum Mutat* 30:1583-90.
- 54 Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. 2008. Replacing PCR with COLD-PCR
55 enriches variant DNA sequences and redefines the sensitivity of genetic testing. *Nat Med*
56 14:579-84.
- 57
58 Milbury CA, Li J, Makrigiorgos GM. 2009. COLD-PCR-enhanced high-resolution melting enables rapid
59 and selective identification of low-level unknown mutations. *Clin Chem* 55:2130-43.
- 60

- 1
2
3 Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. 2009. IDH1 mutations as molecular signature and
4 predictive factor of secondary glioblastomas. *Clin Cancer Res* 15:6002-7.
- 5
6 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL,
7 Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz
8 LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD,
9 Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An
10 integrated genomic analysis of human glioblastoma multiforme. *Science* 321:1807-12.
- 11
12 Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-
13 Xuan K, Delattre JY. 2009. Isocitrate dehydrogenase 1 codon 132 mutation is an important
14 prognostic biomarker in gliomas. *J Clin Oncol* 27:4150-4.
- 15
16 van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC,
17 Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M. 2010. IDH1
18 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic
19 Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment
20 of Cancer Brain Tumor Group. *Clin Cancer Res* 16:1597-604.
- 21
22 Vossen RH, Aten E, Roos A, den Dunnen JT. 2009. High-resolution melting analysis (HRMA): more
23 than just sequence variant screening. *Hum Mutat* 30:860-6.
- 24
25 Wittwer CT. 2009. High-resolution DNA melting analysis: advancements and limitations. *Hum Mutat*
26 30:857-9.
- 27
28 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins
29 GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B,
30 Bigner DD. 2009. IDH1 and IDH2 Mutations in Gliomas. *N Engl J Med* 360:765-773.
- 31
32 Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ,
33 Luthra R. 2009. Application of COLD-PCR for improved detection of KRAS mutations in clinical
34 samples. *Mod Pathol* 22:1023-1031.
- 35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figures legends**
4
5
6
7

8 **Figure 1: Principle of fast COLD PCR performed for the detection of *IDHI*^{R132H}**
9 **mutation in glioma samples.**
10
11

12
13
14
15 **Figure 2: Assays performed to detect *IDHI*^{R132H} mutation in tumor samples.**
16
17

18
19
20 **Figure 3: Comparison of conventional PCR HRM (A), COLD HRM (B) and double**
21 **COLD HRM (C) for the detection of *IDHI*^{R132H} mutation.** Mutant DNA was
22 serially diluted with wild type DNA and each mixture was submitted to the three
23 assays. Sequencing chromatograms after conventional PCR HRM, COLD HRM and
24 double COLD HRM (D).
25
26
27
28
29
30

31 **Figure 4: Detection of *IDHI*^{R132H} mutation in grade II gliomas edges. A. *IDHI*^{R132H}**
32 **immunohistochemistry in patient 8 tumor core (upper panel) and in tumor edge (lower**
33 **panel); magnification x200. B. *IDHI*^{R132H} detection by PCR HRM (upper panel) and**
34 **double COLD PCR HRM (lower panel)**
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **COLD PCR HRM: A HIGHLY SENSITIVE DETECTION METHOD FOR *IDH1***
4
5
6 **MUTATION**
7
8
9
10
11
12
13
14

15 Blandine Boisselier^{1,2,3}, Yannick Marie^{1,2,3}, Marianne Labussière^{1,2,3}, Pietro Ciccarino^{1,2,3},
16
17 Virginie Desestret^{1,2,3,5}, XiaoWei Wang^{1,2,3}, Laurent Capelle⁴, Jean-Yves Delattre^{1,2,3,6}, Marc
18
19 Sanson^{1,2,3,6}
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Affiliations:**
34
35

- 36 1. Université Pierre et Marie Curie-Paris 6, Centre de Recherche de l'Institut du Cerveau et de
37
38 la Moëlle épinière (CRICM) UMR-S975, Paris 75013, France
39
40
41 2. INSERM U 975, Paris 75013, France
42
43
44 3. CNRS, UMR 7225, Paris 75013, France
45
46
47
48 4. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Neurosurgery, Paris 75013,
49
50 France
51
52
53 5. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Laboratoire de Neuropathologie R.
54
55 Escourolle, Paris 75013, France.
56
57
58
59 6. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Service de Neurologie 2, Paris 75013, France
60

1
2
3
4
5
6 **Correspondance to** Dr Marc Sanson, Service de Neurologie Mazarin, Groupe Hospitalier
7
8
9 Pitié-Salpêtrière, 75651, Paris cedex 13, France.

10
11
12 Tel: +33 1 42 16 05 73 Fax: +33 1 42 16 03 75; marc.sanson@psl.ap-hop-paris.fr
13
14
15

16
17
18 **Abbreviations:**
19

20
21 **AII: astrocytoma;** COLD PCR: co-amplification al lower denaturation temperature PCR;
22

23
24 HRM: high resolution melting; **IDH1: isocitrate dehydrogenase 1; OAI: oligoastrocytoma;**
25

26
27 **OII: oligodendrogloma.**
28
29
30
31
32

33 **Disclosures**
34

35
36 The authors report no disclosures.
37
38
39
40
41

42 **Competing interests**
43

44
45 No potential conflicts of interest were disclosed.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Isocitrate dehydrogenase 1 R132H (*IDH1*^{R132H}) mutation is a frequent alteration and a major prognostic marker in gliomas. However, direct sequencing of highly contaminated tumor samples may fail to detect this mutation. Our objective was to evaluate the sensitivity of a newly described amplification method, coamplification at lower temperature-PCR (COLD PCR), combined with high resolution melting (HRM) for the detection of *IDH1*^{R132H} mutation. To this end, we used serial dilutions of mutant DNA with wild type DNA. PCR-HRM assay detects *IDH1*^{R132H} mutation at an abundance of 25%, similar to the detection limit of direct Sanger sequencing. Introducing a run of COLD PCR allows the detection of 2% mutant DNA. Using two consecutive runs of COLD PCR, we detected 0.25% mutant DNA in a background of wild type DNA, that mimicks a tumor sample highly contaminated by normal DNA. We then analyzed ten biopsies of tumor edges, considered free of tumor cells by histological analysis, and showed that immunohistochemistry of *IDH1*^{R132H} was positive in 3 cases (30%), whereas double COLD PCR HRM was positive in the ten cases studied (100%). In summary, COLD PCR HRM analysis is 100-fold more sensitive than Sanger sequencing, rendering this rapid and powerful strategy particularly useful for samples highly contaminated with normal tissue.

Keywords: *IDH1*^{R132H} mutation, COLD PCR, High Resolution Melting, glioma

Introduction

In recent years, recurrent mutations of the gene encoding isocitrate dehydrogenase 1 (*IDH1*; MIM# 147700) have been described at a high frequency in gliomas [Balss, et al., 2008; Bleeker, et al., 2009; Hartmann, et al., 2009; Ichimura, et al., 2009; Parsons, et al., 2008; Sanson, et al., 2009; Yan, et al., 2009]. Mutations in the *IDH1* gene always affect the codon 132, which in more than 90% of cases result in a substitution of arginine by a histidine residue, *IDH1*^{R132H} [Ichimura, et al., 2009; Sanson, et al., 2009; Yan, et al., 2009]. Since it is almost exclusively found in gliomas, *IDH1* mutation has a strong diagnostic value [Yan, et al., 2009]. *IDH1* mutation is also a powerful independent prognostic factor in gliomas [Dubink, et al., 2009; Nobusawa, et al., 2009; Sanson, et al., 2009]: patients with an *IDH1*^{R132H} mutated tumor having a longer survival when compared with those non mutated for the same grade. Given its diagnostic and prognostic potential, the determination of *IDH1* status in glioma samples is gaining increasing attention in clinical practice.

Conventional PCR followed by Sanger sequencing is currently the gold standard in identifying *IDH1* mutations in tumor DNA. Typically, clinical tumor samples are contaminated by normal tissue, thereby diluting the total amount of genetic that is present, and techniques are often required to identify low level alterations within an excess of wild-type DNA. This is particularly true for gliomas which are highly infiltrating tumors [Furnari, et al., 2007]. Conventional PCR enables mutation detection from a very small amount of sample but does not selectively amplify the mutant sequences. Therefore, unless the mutation exceeds a 20-25% abundance relative to wild-type alleles, conventional PCR followed by downstream methods such as Sanger sequencing will fail to detect mutations in clinical samples [Li, et al., 2009; Zuo, et al., 2009]. Enrichment methods are thus necessary to increase the mutant DNA /wild type DNA *ratio*. Tumor-cell enrichment methods, such as cell

1
2
3 sorting or microdissection, are expensive and time-consuming [Zuo, et al., 2009], and
4
5 therefore inadequate for clinical routine use.
6
7

8
9 Recently, co-amplification at lower denaturation temperature PCR (COLD PCR) has
10
11 been described as a powerful method to identify low-level mutations in the *TP53* gene [Li, et
12
13 al., 2008; Milbury, et al., 2009]. This approach uses a critical temperature (T_c) during the
14
15 PCR process in order to enrich mutations at any position of the amplified sequence. Indeed, a
16
17 single nucleotide mismatch anywhere along a double-stranded DNA sequence generates a
18
19 small change in the melting temperature for that sequence, with mutated sequences melting at
20
21 a lower temperature than wild-type sequences [Li, et al., 2008]. During COLD PCR, the
22
23 denaturation temperature is set to T_c , thereby mutation-containing sequences are
24
25 preferentially denatured and available for primers binding and subsequent amplification. High
26
27 Resolution DNA Melting (HRM) analysis is a relatively new and rapid method for detecting
28
29 DNA sequence variants following an initial amplification [Erali, et al., 2008; Vossen, et al.,
30
31 2009; Wittwer, 2009]. Gene scanning by HRM depends on the recognition of changes in the
32
33 shape of the amplicon melting curve that result from heterozygous sequence alterations [Erali,
34
35 et al., 2008]. At the end of PCR amplification, samples are heated to 95°C to ensure a
36
37 complete denaturation. Next, the temperature is reduced to allow cross-hybridization between
38
39 wild-type and mutant sequences, leading to the formation of mismatched heteroduplexes,
40
41 which melt at a lower temperature than wild-type and mutant homoduplex [Vossen, et al.,
42
43 2009]. In this study, we evaluated the sensitivity of different COLD PCR HRM assays for the
44
45 detection of **IDH1^{R132H}** mutation in glioma samples.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Material and methods

DNA and tumors samples

Tumor samples were selected from the Pitié-Salpêtrière brain tumor database. Tumor DNA was extracted from frozen tissues using the QIAmp DNA according to the manufacturer instructions (Qiagen). Samples used in this work have previously been tested for the presence of *IDH1* mutation (reference sequence NM_005896.2) by direct sequencing, as already described [Parsons, et al., 2008; Yan, et al., 2009].

Determination of T_c

We applied the fast COLD PCR assays for detecting *IDH1* mutation based on the methodology described in the literature [Li, et al., 2008], with several modifications. We first determined the new denaturation temperature T_c for the reaction. We used the same primers as for conventional PCR assay, which produced an amplicon of 172 bp. To identify the optimal critical denaturation temperature T_c , a series of COLD PCR reactions at graded temperatures below T_m were performed. We then set the T_c at 81°C, the lowest temperature that reproducibly yielded a substantial PCR. In fast COLD PCR, the reaction protocol began with 20 cycles of conventional amplification for an initial build-up of all amplicons, followed by 30 COLD PCR cycles to selectively enrich for T_m -reduced mutant sequences (Figure 1). COLD PCR assays were performed on a LightCycler480 (Roche Diagnostics Corporation) to ensure a precise control of temperature during the experiments.

Comparison of sensitivities of the different assays to detect *IDH1* mutation

To determine if COLD PCR could enhance the sensitivity of *IDH1*^{R132H} mutation detection, we compared the sensitivity of three experimental protocols. Exon 4 of the *IDH1*

1
2
3 gene was first amplified either by conventional PCR or by fast COLD PCR. A second round
4
5 of amplification was then performed either by PCR HRM, or by fast COLD PCR HRM
6
7 (Figure 2).
8
9

10
11
12
13
14 To compare the sensitivity of the different assays, we performed a serial dilution study
15
16 using a gDNA sample from a grade II oligoastrocytoma patient containing an *IDH1*^{R132H}
17
18 mutation as the source of the mutant allele. This mutation-containing gDNA sample was
19
20 serially diluted into wild-type gDNA (ie blood constitutive gDNA from the same patient) to
21
22 the following percentages: 25%, 10%, 8%, 5%, 4%, 2%, 1%, 0.5%, 0.25%, 0.1%, and 0.05%.
23
24 In addition, wild-type gDNAs (n=7) were included in each experiment. The same experiment
25
26 was reproduced with several other mutated DNA samples: another CGT→CAT mutation
27
28 (Arg132His), and also with other, less frequent mutations, such as CGT→CTT (Arg132Leu)
29
30 and CGT→AGT (Arg132Ser).
31
32
33
34
35
36
37
38

39 First round of amplification

40
41
42 Each PCR amplification reaction contained 50ng gDNA. PCR cycling conditions for
43
44 the first round consisted of an initial denaturation step at 94°C for 5 min; 40 cycles of 94°C
45
46 for 30s; 60°C for 1 min; and 72°C for 1 min30; and final extension at 72°C for 7 min. The
47
48 reactions were carried out using a Mastercycler (Eppendorf). Conventional PCR reactions
49
50 contained final reagent concentrations as follows: 1x PCR Master Mix (Abgene), 0.25 μM
51
52 forward and reverse primers (Invitrogen; Table I) and DNA template. COLD PCR cycling
53
54 conditions on LightCycler480 (Roche Diagnostics Corporation) are summarized as follows:
55
56 96°C, 10 min; 20 cycles of 95°C, 15s; 60°C, 30s, then 30 cycles of 81°C, 15s; 60°C, 30s.
57
58
59
60

1
2
3 COLD PCR assays contained final reagent concentrations as follows: LightCycler480 HRM
4
5 Master (Roche Diagnostics Corporation), 0.25 μ M forward and reverse primers (Invitrogen),
6
7
8 3 mM MgCl₂ and DNA template.
9

14 Second round of amplification

17 PCR amplification was performed with the LightCycler480 (Roche Diagnostics
18 Corporation). Each reaction contained diluted PCR amplicons (1/1000), 0.25 μ M forward and
19
20 reverse primers (Invitrogen, Table I), 3 mM MgCl₂ and LightCycler480 HRM Master (Roche
21
22 Diagnostics Corporation). PCR HRM cycling conditions were as follows: 96°C, 10min; 40
23
24 cycles of 95°C, 30s; 60°C, 30s. COLD PCR HRM cycling conditions are summarized as
25
26 follows: 96°C , 10min; 20 cycles of 95°C, 15s; 60°C, 30s, then 30 cycles of 81°C (T_c), 15s;
27
28 60°C, 30s. After amplification, a post amplification melting curve program was initiated by
29
30 heating to 95°C for 1 min, cooling to 40°C for 1 min, and increasing the temperature to 95°C
31
32 while continuously measuring fluorescence at 25 acquisitions per degree. Each PCR run
33
34 contained a negative (no template) control and each amplification was duplicated.
35
36
37
38
39
40
41

42 High Resolution Melting (HRM) analysis and direct sequencing

45 At the end of the second round of amplification, fluorescent melting curves were
46
47 analyzed using LC480 Gene Scanning software V1.2.9 (Roche Diagnostics Corporation). All
48
49 curves were analyzed following normalization, temperature shifting, automated grouping, and
50
51 the inspection of difference plots. The grouping software uses a curve shape-matching
52
53 algorithm in order to identify wild type from mutant samples. The 0.2 value was chosen for
54
55 the grouping sensitivity in all experiments.
56
57
58
59
60

1
2
3 Products of each assay were then submitted to the sequencing reaction using the
4 BigDye Terminator v3.1 Sequencing Kit (Applied Biosystems) as previously described
5 [Sanson, et al., 2009]. After a purification step using BigDye Xterminator Purification Kit
6 (Applied Biosystems), both forward and reverse sequences were determined on an ABI prism
7 3730 DNA analyzer (Perkin Elmer).
8
9
10
11
12
13
14

15 16 **Tumor sample selection and immunohistochemical detection of *IDH1*^{R132H}**

17
18 Tumors were retrieved from the neuropathology department database according to the
19 following criteria: histological diagnosis of WHO grade II gliomas; presence of *IDH1*^{R132H}
20 mutation confirmed by Sanger sequencing; availability of frozen and paraffin embedded
21 samples of tumor core and tumor edge, with edge biopsies considered as free of infiltrated
22 tumor cells by standard HE staining.
23
24
25
26
27
28
29
30

31
32 Immunohistochemical staining for *IDH1*^{R132H} was performed on 4 µm paraffin
33 sections of formalin-fixed tumor samples using mouse monoclonal anti-R132H-IDH1
34 antibody culture supernatant (a generous gift from Pr A. von Deimling), as previously
35 published [Capper, et al., 2010; Capper, et al., 2009]. Local immunohistochemistry protocol
36 was validated on gliomas samples which were previously analysed by Sanger sequencing for
37 *IDH1*^{R132H} mutation (positive and negative controls). Labelling was defined as positive (at
38 least one cluster of positive tumor cells) or negative (no positive tumor cells detected).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Determination of the sensitivity with dilution studies

To identify the most sensitive method for detecting *IDH1* mutation, we evaluated two techniques after a first stage of conventional PCR: the PCR HRM assay and the COLD PCR HRM assay. In a third assay, we replaced the first conventional PCR by a run of COLD PCR (**Figure 2**). The sensitivity of the three assays was compared using a dilution series obtained by mixing DNA from heterozygous positive control carrying the *IDH1* R132H mutation with wild-type DNA from peripheral blood.

Conventional PCR HRM assay detects mutant DNA at a concentration of 25% in a background of wild-type DNA (**Figure 3A**). In contrast, the COLD PCR HRM assay detects *IDH1*^{R132H} mutation at a much lower concentration: mutant DNA diluted into wild-type DNA to a 2% abundance was still clearly differentiated from normal sequences (**Figure 3B**). Therefore, the COLD PCR HRM assay produced an approximately 10-fold improvement in the *IDH1* mutation detection, as compared to the conventional PCR HRM analysis. Replacing the first conventional PCR amplification by a run of COLD PCR further enhanced selective enrichment of the mutant DNA and improved the detection of *IDH1*^{R132H} mutation. In these conditions, we were able to detect mutant DNA at a concentration as low as 0.25% in mixture with wild-type DNA (**Figure 3C**). Thus, the double COLD PCR HRM assay for the detection of *IDH1*^{R132H} mutation was 100-fold more sensitive than the PCR HRM assay.

To both confirm the selective mutation enrichment and to exclude false positive results, amplicons produced at the end of the three assays were submitted to direct sequencing using the Sanger method. The sequencing chromatograms are presented in Figure 3D. In all three cases, direct sequencing confirmed the presence of the *IDH1*^{R132H} mutation. After

1
2
3 double COLD PCR HRM with 0.25% of mutant DNA/wild DNA, *IDH1*^{R132H} mutation was
4
5 evident as clearly as for 25% with conventional PCR HRM and 2% with COLD PCR HRM.
6
7

8
9 The same results were obtained with another glioma with **CGT→CAT mutation**
10
11 **(Arg132His), and also with less frequent *IDH1*¹³² mutations CGT→CTT (Arg132Leu)**
12
13 **and CGT→AGT (Arg132Ser) (supplementary figure).**
14
15

16 17 18 19 20 **Comparison of PCR HRM, COLD PCR HRM and double COLD PCR HRM and** 21 22 ***IDH1*^{R132H} immunohistochemistry in biopsies of tumor edges** 23 24

25
26 To definitely validate the clinical interest of our technique, we selected 10 pairs of
27
28 tumor core and tumor edge (one astrocytoma, 5 oligodendrogliomas, and 4
29
30 oligoastrocytomas), and performed *IDH1*^{R132H} mutation detection by both
31
32 immunohistochemistry and molecular techniques (**Table II**). *IDH1*^{R132H}
33
34 immunohistochemistry was positive in 3 cases (30%, 2 grade II oligodendrogliomas, and one
35
36 grade II oligoastrocytoma) showing a cytoplasmic granular staining as previously described
37
38 [Capper, et al., 2010]. **Figure 4A** presents the results of immunohistochemistry staining for
39
40 patient 8 in the tumor core and in the biopsy edge (lower panel). PCR HRM was positive in 8
41
42 cases out of 10 (80.0%; **Figure 4B** upper panel). In contrast, both COLD PCR HRM (data not
43
44 shown) and double COLD PCR HRM were positive in all cases (100%; **Figure 4B**, lower
45
46 panel, and **table II**).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Gliomas are characterized by a highly invasive phenotype, with tumor cells invading the brain at a distance far from the bulk of tumor [Furnari, et al., 2007]. Therefore biopsy samples are often contaminated by normal brain tissue, and mutated DNA is diluted in a the background of wild-type DNA from surrounding brain tissue, vasculature, and infiltrating lymphocytes [Dobrowolski, et al., 2009]. Because *IDH1*^{R132H} mutation is almost restricted to gliomas [Yan, et al., 2009], it has a major diagnostic potential. Therefore a fast and reliable scanning technique to detect this mutation in clinical samples with very few tumor cells (and appearing therefore normal at neuropathological analysis) is particularly important. In addition *IDH1*^{R132H} mutation is a major prognostic factor [Sanson, et al., 2009; van den Bent, et al., 2010]. Simple HRM has been very recently reported as a fast and sensitive strategy, detecting IDH1 and IDH2 mutations in a 90% normal DNA background [Horbinski, et al., 2010]. In this study, we used fast COLD PCR to selectively amplify *IDH1*^{R132H} mutated DNA and we showed that double COLD PCR HRM assay is a highly reliable method to detect *IDH1* mutation in samples with very few tumor cells (up to 0.25% mutated/non mutated DNA). In addition, this assay is fast (less than three hours) and therefore particularly suitable for routine diagnosis purposes in neuropathology.

Despite *IDH1*^{R132H} accounts for more than 90% of *IDH1* mutations reported in gliomas, other mutations have been described: CGT→AGT, CGT→CTT CGT→GGT, CGT→TGT [Balss, et al., 2008; Gravendeel, et al., 2010; Sanson, et al., 2009; Yan, et al., 2009]. Fortunately, all these mutations, except the CGT→GGT change, result in a lower T_m, rendering them theoretically detectable by our simple double COLD PCR assay. Indeed we were able to detect some of these less frequent mutations (supplementary figure). For the detection of CGT→GGT, a full COLD PCR assay –allowing the enrichment of all possible

1
2
3 mutations- could be performed, though the selective amplification *ratio* will probably be
4
5 lower than in fast COLD PCR, because amplification, and thus enrichment in mutant
6
7 sequences, begins earlier during cycling in fast COLD PCR than in full COLD PCR [Li, et al.,
8
9 2008; Milbury, et al., 2009].
10
11

12
13 We showed that double COLD PCR HRM (followed by sequencing in case of aberrant
14
15 HRM profiles) is a powerful method to evidence the presence of tumor cells with IDH1
16
17 mutation in apparently “blank” biopsies of grade II gliomas, and is much more sensitive than
18
19 immunohistochemistry for *IDH1*^{R132H}. Such procedure may be particularly useful in lesions
20
21 radiologically highly suggestive of glioma, whose biopsy appears non contributive because of
22
23 the very low proportion of tumor cells. In such cases, finding an *IDH1* mutation will confirm
24
25 the diagnosis of glioma, avoiding a further invasive procedure to establish diagnosis.
26
27 Moreover, such approach could also be suitable for *IDH1*^{R132H} mutation detection in the
28
29 cerebral spinal fluid thus confirming glioma diagnosis without the need for surgery.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

Work supported by the Association pour la Recherche sur les Tumeurs Cérébrales (ARTC) and the Association pour la Recherche contre le Cancer (ARC). ML is supported by a grant from the Association pour la Recherche contre le Cancer (ARC). We are indebted to Pr A von Deimling for providing the mouse monoclonal anti-R132H-IDH1 antibody and to Alice Brunker for editing the manuscript.

For Peer Review

References

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. 2008. Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 116:597-602.
- Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A. 2009. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Hum Mutat* 30:7-11.
- Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A. 2010. Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. *Brain Pathol* 20:245-54.
- Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. 2009. Monoclonal antibody specific for IDH1 R132H mutation. *Acta Neuropathol* 118:599-601.
- Dobrowolski SF, Hendrickx AT, van den Bosch BJ, Smeets HJ, Gray J, Miller T, Sears M. 2009. Identifying sequence variants in the human mitochondrial genome using high-resolution melt (HRM) profiling. *Hum Mutat* 30:891-8.
- Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ. 2009. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. *Neurology* 73:1792-5.
- Erali M, Voelkerding KV, Wittwer CT. 2008. High resolution melting applications for clinical laboratory medicine. *Exp Mol Pathol* 85:50-8.
- Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. 2007. Malignant astrocytic glioma: genetics, biology, and paths to treatment. *Genes Dev* 21:2683-710.
- Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Smitt PA, French PJ. 2010. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. *Hum Mutat* 31:E1186-99.
- Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. 2009. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. *Acta Neuropathol* 118:469-74.
- Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN. 2010. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. *J Mol Diagn* 12:487-92.

- 1
2
3 Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP. 2009. IDH1
4 mutations are present in the majority of common adult gliomas but rare in primary
5 glioblastomas. *Neuro Oncol* 11:341-7.
6
7 Li J, Milbury CA, Li C, Makrigiorgos GM. 2009. Two-round coamplification at lower denaturation
8 temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-
9 level mutations in lung adenocarcinoma. *Hum Mutat* 30:1583-90.
10
11 Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM. 2008. Replacing PCR with COLD-PCR
12 enriches variant DNA sequences and redefines the sensitivity of genetic testing. *Nat Med*
13 14:579-84.
14
15 Milbury CA, Li J, Makrigiorgos GM. 2009. COLD-PCR-enhanced high-resolution melting enables rapid
16 and selective identification of low-level unknown mutations. *Clin Chem* 55:2130-43.
17
18 Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. 2009. IDH1 mutations as molecular signature and
19 predictive factor of secondary glioblastomas. *Clin Cancer Res* 15:6002-7.
20
21 Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL,
22 Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz
23 LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD,
24 Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. 2008. An
25 integrated genomic analysis of human glioblastoma multiforme. *Science* 321:1807-12.
26
27 Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-
28 Xuan K, Delattre JY. 2009. Isocitrate dehydrogenase 1 codon 132 mutation is an important
29 prognostic biomarker in gliomas. *J Clin Oncol* 27:4150-4.
30
31 van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC,
32 Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M. 2010. IDH1
33 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic
34 Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment
35 of Cancer Brain Tumor Group. *Clin Cancer Res* 16:1597-604.
36
37 Vossen RH, Aten E, Roos A, den Dunnen JT. 2009. High-resolution melting analysis (HRMA): more
38 than just sequence variant screening. *Hum Mutat* 30:860-6.
39
40 Wittwer CT. 2009. High-resolution DNA melting analysis: advancements and limitations. *Hum Mutat*
41 30:857-9.
42
43 Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins
44 GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B,
45 Bigner DD. 2009. IDH1 and IDH2 Mutations in Gliomas. *N Engl J Med* 360:765-773.
46
47 Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ,
48 Luthra R. 2009. Application of COLD-PCR for improved detection of KRAS mutations in clinical
49 samples. *Mod Pathol* 22:1023-1031.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figures legends**
4
5
6
7

8 **Figure 1: Principle of fast COLD PCR performed for the detection of $IDHI^{R132H}$**
9 **mutation in glioma samples.**
10
11

12
13
14
15 **Figure 2: Assays performed to detect $IDHI^{R132H}$ mutation in tumor samples.**
16
17

18
19
20 **Figure 3: Comparison of conventional PCR HRM (A), COLD HRM (B) and double**
21 **COLD HRM (C) for the detection of $IDHI^{R132H}$ mutation.** Mutant DNA was
22 serially diluted with wild type DNA and each mixture was submitted to the three
23 assays. Sequencing chromatograms after conventional PCR HRM, COLD HRM and
24 double COLD HRM (D).
25
26
27
28
29
30

31 **Figure 4: Detection of $IDHI^{R132H}$ mutation in grade II gliomas edges. A. $IDHI^{R132H}$**
32 **immunohistochemistry in patient 8 tumor core (upper panel) and in tumor edge (lower**
33 **panel); magnification x200. B. $IDHI^{R132H}$ detection by PCR HRM (upper panel) and**
34 **double COLD PCR HRM (lower panel)**
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table I: Primers used for first and second rounds of amplification

	Primer	Amplicon length
First amplification	Forward CGGTCTTCAGAGAAGCCATT	172 bp
	Reverse CACATACAAGTTGGAAATTTCTGG	
Second amplification	Forward CGGTCTTCAGAGAAGCCATT	129 bp
	Reverse GCAAAATCACATTATTGCCAAC	

Table II: Comparison of IDH1^{R132} immunohistochemistry with PCR HRM and double COLD PCR HRM for the detection of IDH1^{R132H} mutation in tumor edges. For all techniques, results are expressed as positive (+) or negative (-). COLD PCR HRM (data not shown) gave the same results as double COLD PCR HRM.

Patients	Histology	IDH1 ^{R132} immunohistochemistry		PCR HRM		Double COLD PCR HRM	
		Tumor core	Tumor edge	Tumor core	Tumor edge	Tumor core	Tumor edge
1	OAI	+	-	+	+	+	+
2	OII	+	-	+	-	+	+
3	AI	+	-	+	+	+	+
4	OAI	+	-	+	+	+	+
5	OAI	+	+	+	+	+	+
6	OII	+	-	+	+	+	+
7	OII	+	+	+	+	+	+
8	OII	+	+	+	+	+	+
9	OAI	+	-	+	+	+	+
10	OII	+	-	+	-	+	+

All: grade II oligoastrocytoma; OAI: oligoastrocytoma; OII: oligodendroglioma.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1
167x64mm (300 x 300 DPI)

Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2
134x77mm (300 x 300 DPI)





Figure 3
189x292mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




160x90mm (150 x 150 DPI)

Pre Review




Supplementary figure showing conventional PCR HRM (top), COLD HRM (middle) and double COLD HRM (bottom) for several different mutations of IDH1 codon 132.

MUTATION CGT → CTT




MUTATION CGT → CTT

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




MUTATION CGT → AGT

PCR HRM



COLD HRM



Double COLD HRM

